Navigation Links
Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
Date:2/9/2009

LAUSANNE, Switzerland and PARIS, February 9 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Pharmaleads SAS, a science driven drug discovery and early development company, today announced the signature of an exclusive license agreement for the development, registration and commercialisation of a small molecule called Debio 0827 or PL37, about to enter phase I clinical trials. Debio 0827 is the first in a new class of painkillers that could be used in the treatment of chronic pain conditions, primarily in neuropathic pain. Under the terms of the agreement, Debiopharm will make an up-front payment to Pharmaleads, as well as further payments as Pharmaleads reaches predefined development milestones.

"With this agreement we add the new therapeutic area of chronic pain management to the Debiopharm product portfolio. There is currently an unmet medical need for the treatment of chronic pain, which can often not be treated successfully and can seriously affect patients' quality of life. For this reason, we have decided to develop this new therapeutic approach," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group.

"This exclusive licence agreement is very exciting and promising: it will speed up the development of a totally new class of painkillers, hence confirming the validity of our science and chemistry, as well as our capabilities as a drug discovery and early development company," added Thierry Bourbie, Chairman and CEO of Pharmaleads.

Following authorisation from the French Medicine Agency (AFSSAPS), Debio 0827 is about to enter a single ascending dose Phase I, randomised, double-blind, placebo controlled single oral dose escalation study in France, to investigate its safety, tolerability and pharmacokinetics in healthy volunteers.

About N
'/>"/>

SOURCE Pharmaleads
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
2. Japanese Cancer Association and Debiopharm Honour Japanese Research
3. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
4. Debiopharm and EPFL Establish an Oncology Chair
5. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
6. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
7. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
8. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
9. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
10. Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University
11. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2, 2015 Amici Procurement Migrates ... company Amici Procurement has chosen Microsoft Cloud Solution Provider ... to Office 365.      (Logo: http://photos.prnewswire.com/prnh/20121126/579634) , ... medium-sized companies in the bio-tech sector with a unique ... purchasing cycle to help them obtain best value. Its ...
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech ... surgical instruments in Orthopedics, announced today the acquisition of Turner Medical, Inc ... provider of surgical instruments to the Spine Industry. The acquisition of Turner Medical ...
(Date:7/1/2015)... and PARIS , July 1, ... Genective, key developer of biotech crops, today announce ... new generations of insect control traits. ... counter the realities of advancing insect resistance. We ... unique insect control technology with Genective,s capability in ...
(Date:7/1/2015)... ... ... The next-generation sequencing (NGS) clinical market is poised for huge growth as it prepares ... in its new report that the market drivers of this vibrant industry include increased ... diagnostics as part of a molecular diagnostics trend. , The global market is forecast ...
Breaking Biology Technology:Biotech Procurement Company Moves to Office 365 with iomart 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3AgBiome and Genective collaborate to create novel insect-resistant crops 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3
... MILWAUKEE -- With the new school semester just ... Marquette University, however, is hoping that illegal Internet downloading ... is the first university working with the Business ... including, Microsoft, Apple and Adobe. The BSA's Define ...
... take it for granted the lights will always be on ... temporarily bring down power lines and interrupt electrical service to ... power will always be there - day in, day out ... as easy as flipping a switch. While Wisconsin has come ...
... Madison, Wis. -- Gov. Jim Doyle says taxpayers ... a total of nearly $80 million over the lifetime ... goods and services, including a number of technology areas. ... Accountability, Consolidation, and Efficiency (ACE) Initiative to ...
Cached Biology Technology:Marquette targets illegal downloading 2Marquette targets illegal downloading 3Keeping Wisconsin supplied with energy won't get any easier 2Keeping Wisconsin supplied with energy won't get any easier 3
(Date:6/23/2015)... , June 23, 2015   MedNet Solutions ... supports the entire spectrum of clinical research, is ... ™ , the company,s intuitive, flexible and ... a Silver 2015 Stevie® Award by the ... & Services Website category.  The American Business Awards ...
(Date:6/23/2015)... , June 23, 2015   Valencell, ... announced the results of a recent study that ... on the wrist during activity. In a study ... was compared along with the Apple Watch against ... measuring heart rate during activity. The study demonstrated ...
(Date:6/18/2015)... , June 18, 2015 This report ... Million by the following Product Segments, which includes Immunoassay ... Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay ... US, Canada , Japan ... Asia-Pacific , Latin America , ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... helped open a new door of possibility in the high-stakes ... an international team, the scientists including Stanford Woods Institute ... found a way to create future ocean conditions in a ... the device can mimic the composition of the future ocean ...
...   Masimo (NASDAQ: MASI ... 33-month group purchasing renewal agreement with the Premier ... organization. The new agreement allows Premier members, at their ... pre-negotiated by Premier for Masimo,s complete market-leading line of ...
... Washington, DCJune 6, 2012 Anthony R. Richardson, Ph.D., Assistant ... Carolina Hill School of Medicine, has been honored with ... Awards. These awards, given annually to two young scientists ... medical microbiology and infectious diseases, are presented in memory ...
Cached Biology News:Stanford researchers help predict the oceans of the future with a mini-lab 2Premier Healthcare Renews Supplier Agreement with Masimo 2Premier Healthcare Renews Supplier Agreement with Masimo 3Premier Healthcare Renews Supplier Agreement with Masimo 4Premier Healthcare Renews Supplier Agreement with Masimo 5Premier Healthcare Renews Supplier Agreement with Masimo 6The American Society for Microbiology honors Anthony R. Richardson 2
Request Info...
... Kit Contains the following: , Coated Capture Antibody: ... , Wash/Sample Diluent: 300 mL of 2X concentrate ... 10 microg lyophilized peptide , Lyophilized Standard Diluent: ... 50X concentrate , Secondary Antibody-HRP: 30 microL of ...
carnitine deficiency-associated gene expressed in ventricle 1...
... Clone/PAD: ZMD.471. Immunogen: Synthetic peptide ... the mouse junctophilin-1. Specificity: Specific ... Mouse (positive controls: mouse brain and ... and skeletal muscle tissues). Applications: ...
Biology Products: